EMA pre­pares for changes to non-in­fe­ri­or­i­ty, equiv­a­lence study guid­ance

The Eu­ro­pean Med­i­cines Agency is gear­ing up to make changes to its decades-old guide­lines for how drug spon­sors should use non-in­fe­ri­or­i­ty and equiv­a­lence stud­ies to com­pare new prod­ucts to ex­ist­ing ones.

In a con­cept pa­per pub­lished Fri­day for the up­com­ing guide­line, the EMA laid out its plans to merge its ex­ist­ing doc­u­ments on non-in­fe­ri­or­i­ty that were pub­lished near­ly two decades ago. Com­ments on the doc­u­ment are due by the end of May.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER